Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality

Critical Care Medicine

Volumn 28, Issue 7, 2000, Pages 2344-2354

  Presneill, Jeffrey J ^a   Harley, Nerina S ^a   Wilson, John W ^a   Cade, John F ^a   Waring, Paul M ^b   Layton, Judith E ^b   Maher, Darryl W ^b   Cebon, Jonathan ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Colony stimulating factor; Cytokine; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Interleukin 6; Leukemia inhibitory factor; Mortality; Multiple organ dysfunction; Sepsis; Septic shock

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; GRANULOCYTE; HOSPITALIZATION; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SHOCK;

EID: 0033852979     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200007000-00028     Document Type: Article

References (70)

1. 1. Metcalf D, Nicola NA: The hemopoietic colony-stimulating factors: From biology to clinical applications. Cambridge, Cambridge University Press, 1995
2. 2. Fujishima S, Aikawa N: Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 1995; 21:277-285
3. 3. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997; 61:647-653
4. 4. Demling RH: The modern version of adult respiratory distress syndrome. Annu Rev Med 1995; 46:193-202
5. 5. Pittet JK, Mackersie RC, Martin TR, et al: Biological markers of acute lung injury: Prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155: 1187-1205
6. 6. Baughman RP, Gunther KL, Rashkin MC, et al: Changes in the inflammatory response of the lung during acute respiratory distress syndrome: Prognostic indicators. Am J Respir Crit Care Med 1996; 154:76-81
7. 7. Eichacker PQ, Farese A, Hoffman WD, et al: Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis 1992; 145:1023-1029
8. 8. Foster R, Metcalf D, Robinson WA, et al: Bone marrow colony stimulating activity in human sera. Br J Haematol 1968; 15: 147-159
9. 9. Kragsbjerg P, Holmberg H, Vikerfors T: Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Dis 1996; 28:391-398
10. 10. Kawakami M, Tsutsumi H, Kumakawa T, et al: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990; 76:1962-1964
11. 11. Watari K, Asano S, Shirafuji N, et al: Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989; 73:117-122
12. 12. Tanaka H, Ishikawa K, Nishino M, et al: Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996; 40:718-726
13. 13. Cebon J, Layton JE, Maher D, et al: Endogenous hemopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86:265-274
14. 14. Waring PM, Presneill JJ, Maher DW, et al: Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 1995; 102: 501-506
15. 15. Lieschke GJ, Burgess AW: Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (first of two parts). N Engl J Med 1992; 327:28-35
16. 16. Lieschke GJ, Burgess AW: Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (second of two parts). N Engl J Med 1992; 327:99-106
17. 17. Maher DW: Clinical use of cytokines. In: Garland JM, Quesenberry PJ, Hilton DJ, (Eds). Colony-Stimulating Factors: Molecular and Cellular Biology. Second Edition. New York, Marcel Dekker, 1997, pp 547-560
18. 18. Nishida T, Hasegawa J, Nakao K: Granulocyte colony-stimulating factor for gastrointestinal perforation in patients with leukopenia. J Trauma 1996; 40:727-732
19. 19. Wunderink RG, Leeper KV, Schein RMH, et al: Clinical response to Filgrastim (rmetHuG-CSF) in pneumonia with severe sepsis. Abstr. Am J Respir Crit Care Med 1996; 153(4 part 2):A123
20. 20. Nelson S, Belknap SM, Carlson RW, et al: A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 1998; 178:1075-1080
21. 21. Root RK, Dale DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179(Suppl 2):S342-S352
22. 22. Gross-Weege W, Weiss M, Schneider M, et al: Safety of low dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 1997; 23:16-22
23. 23. Garber BG, Hébert PC, Yelle JD, et al: Adult respiratory distress syndrome: A systematic overview of incidence and risk factors. Crit Care Med 1996; 24:687-695
24. 24. Fink MP, O'Sullivan BP, Menconi MJ, et al: Effect of granulocyte-colony stimulating factor on systemic and pulmonary responses to endotoxin in pigs. J Trauma 1993; 34: 571-577
25. 25. Toda H, Murata A, Oka Y, et al: Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood 1994; 83:2893-2898
26. 26. Villers D, Dao T, Nguyen J-M, et al: Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. J Infect Dis 1995; 171:232-236
27. 27. Waring PM, Waring LJ, Metcalf D: Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis 1994; 170: 1224-1228
28. 28. Moscovitz H, Shofer F, Mignott H, et al: Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994; 22:1102-1107
29. 29. Friedland JS, Porter JC, Daryanani S, et al: Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med 1996; 24:1775-1781
30. 30. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in humans: IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
31. 31. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
32. 32. Cullen DJ: Results and costs of intensive care. Anesthesiology 1977; 2:203-216
33. 33. Members of the American College of Chest Physicians/Society of Critical Care Medicine: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
34. 34. Pinsky MR, Vincent J-L, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575
35. 35. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:1-5
36. 36. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
37. 37. Matthews JNS, Altman DG, Campbell MJ, et al: Analysis of serial measurements in medical research. BMJ 1990; 300:230-235
38. 38. Hosmer DW, Lemeshow S: Applied logistic regression. New York, John Wiley and Sons, 1989
39. 39. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
40. 40. Pittet D, Rangel-Frausto MS, Li N, et al: Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 1995; 21: 302-309
41. 41. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995; 274:968-974
42. 42. Kennon C, Overturf G, Bessman S, et al: Granulocyte colony-stimulating factor as a marker for bacterial infections in neonates. J Pediatr 1996; 128:765-769
43. 43. Waage A, Steinshamn S: Cytokine mediators of septic infections in the normal and granulocytopenic host. Eur J Haematol 1993; 50: 243-249
44. 44. Halstensen A, Ceska M, Brandtzaeg P, et al: Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis 1993; 167: 471-475
45. 45. Marchant A, Deviere J, Byl B, et al: Interleukin-10 production during septicemia. Lancet 1994; 343:707-708
46. 46. van der Poll T, Fischer E, Coyle SM, et al: Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. J Infect Dis 1995; 172:577-580
47. 47. Fisher CJ, Dinarello CA: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-1843
48. 48. Kragsbjerg P, Jones I, Vikerfors T, et al: Diagnostic value of blood cytokine concentrations in acute pneumonia. Thorax 1995; 50: 1253-1257
49. 49. Waring PM: Leukemia inhibitory factor. In: Garland JM, Quesenberry PJ, Hilton DJ (Eds). Colony-Stimulating Factors: Molecular and Cellular Biology. Second Edition. New York, Marcel Dekker, 1997, pp 467-513
50. 50. Kishimoto T, Akira S, Narazaki M, et al: Interleukin-6 family of cytokines and gp130. Blood 1995; 84:1243-1254
51. 51. Layton JE, Hockman H, Sheridan WB, et al: Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor. Blood 1989; 74:1303-1307
52. 52. Damas P, Canivet J-L, De Groote D, et al: Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25:405-412
53. 53. Lieschke GJ, Grail D, Hodgson G, et al: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-1746
54. 54. Nishinakamura R, Miyajima A, Mee PJ, et al: Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 1996; 88:2458-2464
55. 55. Kuhns DB, Alvord WG, Gallin JI: Increased circulating cytokines, cytokine antagonists, and e-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171:145-152
56. 56. Rasko JEJ: Granulocyte-macrophage colony-stimulating factor and its receptor. In: Garland JM, Quesenberry PJ, Hilton DJ (Eds). Colony-Stimulating Factors: Molecular and Cellular Biology. Second Edition. New York, Marcel Dekker, 1997, pp 163-201
57. 57. Metcalf D, Rasko JEJ: Leukemic transformation of immortalized FDC-P1 cells engrafted in GM-CSF transgenic mice. Leukemia 1993; 7:878-886
58. 58. O'Reilly M, Silver GM, Greenhalgh DG, et al: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992; 33:679-682
59. 59. Göergen I, Hartung T, Leist M, et al: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 1992; 149:918-924
60. 60. Kanazawa M, Ishizaka A, Hasegawa N, et al: Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. Am Rev Respir Dis 1992; 145:1030-1035
61. 61. Koizumi T, Kubo K, Shinozaki S, et al: Granulocyte colony-stimulating factor does not exacerbate endotoxin-induced lung injury in sheep. Am Rev Respir Dis 1993; 148:132-137
62. 62. Toda H, Murata A, Matsuura N, et al: Therapeutic efficacy of granulocyte colony-stimulating factor against rat cecal ligation and puncture model. Stem Cells 1993; 11: 228-234
63. 63. Lorenz W, Reimund KP, Weitzel F, et al: Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. Surgery 1994; 116:925-934
64. 64. Eichacker PQ, Waisman Y, Natanson C, et al: Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994; 77: 2366-2373
65. 65. Smith WS, Sumnicht GE, Sharpe RW, et al: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: Analysis of survival and multisystem organ failure. Blood 1995; 86: 1301-1309
66. 66. Lundblad R, Nesland JM, Giercksky K-E: Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med 1996; 24:820-826
67. 67. Dunne JR, Dunkin BJ, Nelson S, et al: Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. J Surg Res 1996; 61:348-354
68. 68. deBoisblanc BP, Mason CM, Andresen J, et al: Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. Respir Med 1997; 91:387-394
69. 69. Knaus WA, Wagner DP, Harrell FE: What determines prognosis in sepsis? In: Sibbald WJ, Vincent J-L (Eds). Clinical Trials for the Treatment of Sepsis. Heidelberg, Springer-Verlag, 1995, pp 141-156
70. 70. Calandra T, Baumgartner J-D, Grau GE, et al: Prognostic value of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161:982-987